Table of contents
June 2004 Vol 3 No 6
In this issue
p461 | doi:10.1038/nrd1433
Editorial: In praise of hunting
p463 | doi:10.1038/nrd1432
News and Analysis
News
Mutations predict gefitinib response
p465 | doi:10.1038/nrd1435
News
Therapeutic area influences drug development costs
p466 | doi:10.1038/nrd1436
News
Stand by your brand
p466 | doi:10.1038/nrd1437
News
FDA rejects OTC status for contraceptive | Off-label use of gabapentin reprimanded | Approval for new antithrombotic | First statin to be sold over the counter | Pfizer shifts R&D strategy | NIH addresses staff conflicts of interest | Antisense cancer drug shows no effect on survival
p467 | doi:10.1038/nrd1438
Patent watch
Hydrosol definition crucial
p468 | doi:10.1038/nrd1422
Patent watch
Apotex wins latest round in generic Paxil litigation
p468 | doi:10.1038/nrd1423
Patent watch
Housey loses patents
p468 | doi:10.1038/nrd1439
Patent primer
Novelty: new products and processes
p469 | doi:10.1038/nrd1421
An Audience With
Richard D. Klausner
p470 | doi:10.1038/nrd1430
From the analyst's couch
Colorectal cancer market
p471 | doi:10.1038/nrd1419
Fresh from the Pipeline
Efalizumab
p473 | doi:10.1038/nrd1420
Research Highlights
Metabolic syndrome: Two for the price of one
p475 | doi:10.1038/nrd1429
Chemical biology: Building blocks for peptide drugs
p476 | doi:10.1038/nrd1424
Pharmacodynamics: PET power
p476 | doi:10.1038/nrd1425
Computational chemistry: Sifting success
p477 | doi:10.1038/nrd1426
In brief
Pharmacogenetics | HIV-1 | Antisense
p478 | doi:10.1038/nrd1427
Anticancer drugs: To the rescue?
p478 | doi:10.1038/nrd1428
Reviews
GSK3 inhibitors: development and therapeutic potential
Philip Cohen & Michel Goedert
p479 | doi:10.1038/nrd1415
Antibody-targeted radiation cancer therapy
Diane E. Milenic, Erik D. Brady & Martin W. Brechbiel
p488 | doi:10.1038/nrd1413
Targeted therapy for brain tumours
Maciej S. Lesniak & Henry Brem
p499 | doi:10.1038/nrd1414
Antimalarial drug discovery: efficacy models for compound screening
David A. Fidock, Philip J. Rosenthal, Simon L. Croft, Reto Brun & Solomon Nwaka
p509 | doi:10.1038/nrd1416
Perspectives
Opinion
Science, pharmacoeconomics and ethics in drug R&D: a sustainable future scenario?
Paolo Preziosi
p521 | doi:10.1038/nrd1418
Innovation
Microbubbles in medical imaging: current applications and future directions
Jonathan R. Lindner
p527 | doi:10.1038/nrd1417
Careers and Recruitment
Career focus
Correspondence
Correspondence: Assessing synergy or antagonism for drug combinations
Angus Bell & Stella G. Machado
| doi:10.1038/nrd1416-c1
